SCHEMBL23846331

SCHEMBL23846331

COc1ccc(NC(=O)c2cccc(-c3cnco3)c2)cc1S(=O)(=O)Nc1c(C)cccc1C

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 11/20 0.53
MAPT P10636 4/20 0.48
KDM4E B2RXH2 3/20 0.48
POLB P06746 2/20 0.48
GAA P10253 2/20 0.48
HCRTR1 O43613 1/20 0.48
HCRTR2 O43614 1/20 0.48
HTT P42858 1/20 0.48
IMPDH1 P20839 1/20 0.47
EDNRA P25101 1/20 0.46
LMNA P02545 3/20 0.45
ALDH1A1 P00352 2/20 0.45
NPC1 O15118 1/20 0.45
PKM P14618 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758307 0.86 ABL1 (0.53) MAPTKDM4EPOLBGAAHCRTR1
SCHEMBL23846619 0.85 ALPL (0.52) MAPTKDM4EPOLBGAAHCRTR1
SCHEMBL23846386 0.84 MEN1 (0.55) MAPTKDM4EPOLBGAAHCRTR1
SCHEMBL23846480 0.82 GRM4 (0.51) MAPTKDM4EPOLBGAAHCRTR1
SCHEMBL25758295 0.82 MAPT (0.52) MAPTKDM4EPOLBGAAHCRTR1
SCHEMBL25758282 0.81 HTR2A (0.48) MAPTKDM4EPOLBGAAHCRTR1
SCHEMBL23846564 0.80 HCRTR1 (0.50) MAPTKDM4EPOLBGAAHCRTR1
SCHEMBL25755382 0.80 MAPT (0.52) MAPTKDM4EPOLBGAAHCRTR1
SCHEMBL23846415 0.79 MAPT (0.49) MAPTKDM4EPOLBGAAHTT
SCHEMBL25758432 0.79 MAPT (0.49) MAPTKDM4EPOLBGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
WO-2021188880-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 IMPDH2 3546/4885MAPT 89/4885KDM4E 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.